IRIS
PASQUINUCCI, Lorella Giuseppina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.536
EU - Europa 4.242
AS - Asia 3.797
AF - Africa 602
SA - Sud America 593
Continente sconosciuto - Info sul continente non disponibili 343
OC - Oceania 13
Totale 18.126
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.241
SG - Singapore 1.785
IT - Italia 1.434
RU - Federazione Russa 1.226
CN - Cina 1.034
BR - Brasile 472
IE - Irlanda 413
CI - Costa d'Avorio 307
UA - Ucraina 283
VN - Vietnam 272
CA - Canada 200
FR - Francia 200
KR - Corea 188
DE - Germania 187
BD - Bangladesh 128
SN - Senegal 118
GB - Regno Unito 109
NG - Nigeria 79
IN - India 74
SE - Svezia 66
ES - Italia 64
JP - Giappone 59
HK - Hong Kong 53
FI - Finlandia 48
NL - Olanda 48
MX - Messico 42
PL - Polonia 41
ID - Indonesia 38
ZA - Sudafrica 33
AR - Argentina 30
TR - Turchia 27
IQ - Iraq 26
BE - Belgio 21
EC - Ecuador 21
UZ - Uzbekistan 19
VE - Venezuela 17
CO - Colombia 16
AT - Austria 15
CL - Cile 15
KE - Kenya 15
CH - Svizzera 14
CR - Costa Rica 14
JM - Giamaica 14
AE - Emirati Arabi Uniti 13
BJ - Benin 13
AU - Australia 12
CZ - Repubblica Ceca 12
LT - Lituania 12
PK - Pakistan 12
GR - Grecia 10
IR - Iran 10
MA - Marocco 10
LB - Libano 9
TN - Tunisia 9
HU - Ungheria 8
PY - Paraguay 8
DZ - Algeria 6
EG - Egitto 6
IL - Israele 6
PE - Perù 6
SA - Arabia Saudita 6
RS - Serbia 5
AZ - Azerbaigian 4
BB - Barbados 4
BG - Bulgaria 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
PH - Filippine 3
TH - Thailandia 3
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
HR - Croazia 2
LV - Lettonia 2
NI - Nicaragua 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
EE - Estonia 1
EU - Europa 1
GD - Grenada 1
Totale 17.770
Salva come PNG Salva come JPEG
Città #
Dallas 1.830
Singapore 1.054
Santa Clara 811
San Jose 595
Chandler 584
Moscow 538
Houston 484
Ashburn 469
Dublin 410
Catania 383
Chicago 341
Abidjan 307
Jacksonville 284
Hefei 229
Boardman 187
Council Bluffs 187
Seoul 187
Beijing 174
Los Angeles 149
Lauterbourg 125
Dakar 118
Nanjing 115
Cambridge 109
Andover 108
Lawrence 108
Toronto 104
Civitanova Marche 98
New York 94
Ho Chi Minh City 81
Rome 81
Bremen 60
Buffalo 60
São Paulo 59
Wilmington 56
Hanoi 52
Des Moines 50
Tokyo 50
Hong Kong 49
San Mateo 47
The Dalles 45
Naples 42
Columbus 39
Lagos 39
Grafing 35
Munich 35
Shenyang 35
Atlanta 33
Nanchang 33
Milan 32
Montreal 32
Saint Petersburg 32
Warsaw 32
Brooklyn 30
Abuja 29
Denver 29
Orem 28
London 27
Messina 27
Changsha 26
Ottawa 26
Jiaxing 25
Johannesburg 22
Phoenix 22
Hebei 21
Poplar 21
Amsterdam 20
Brussels 20
Frankfurt am Main 20
Helsinki 20
Jakarta 19
Pune 18
Rio de Janeiro 18
Seattle 18
Tianjin 18
Da Nang 17
Palermo 17
Chennai 16
Falls Church 15
Haiphong 15
Mexico City 15
Paris 15
San Francisco 15
Lappeenranta 14
Madrid 14
San Giovanni la Punta 14
Tashkent 14
Turku 14
Belo Horizonte 13
Cotonou 13
Marseille 12
San Gregorio di Catania 12
Bologna 11
Dong Ket 11
Port Harcourt 11
San José 11
Stockholm 11
Augusta 10
Baghdad 10
Ningbo 10
Norwalk 10
Totale 12.135
Salva come PNG Salva come JPEG
Nome #
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 483
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 414
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 325
The simultaneous activation of μ- and δ-opioid receptors by (−)-2S-LP2 rescues allodynia with the contribution of TGF-β1 signaling in a rat chronic constriction injury model 235
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 212
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 208
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 204
Do vitamins halt the COVID-19-evoked pro-inflammatory cytokines involved in the development of neuropathic pain? 198
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 198
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 191
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 190
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 187
Caspase-3 activation in human melanoma A375 cell line by a novel selective sigma-2 agonist 184
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 175
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 169
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 168
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 166
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 165
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 162
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 161
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 161
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 158
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 158
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 154
Intercellular communication and ion channels in neuropathic pain chronicization 154
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 152
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 150
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 150
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 148
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 147
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 146
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 145
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 143
Design of Small Molecules for Oncological and Neurodegenerative Diseases 142
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 142
MOR/DOR targeting: an useful strategy in pain management 141
Design and synthesis of trans-decahydroisoquinoline derivatives as new tramadol-like ligands 140
Dual-target ligands and pain: our experience 139
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 139
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 138
Analgesici oppioidi: nuove opportunità nella terapia del dolore 138
From plant to bench: natural products as source for analgesic drug development. 138
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 137
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 137
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 136
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 135
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 135
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 135
Bivalent opioid peptides synthesized from μ selective monomers display preferential selectivity for δ receptors 134
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 133
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 132
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 131
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 131
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 127
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 126
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 126
Enhancing HDAC Inhibitor Screening: Addressing Zinc Parameterization and Ligand Protonation in Docking Studies 126
Analgesici oppioidi 125
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 122
From Plant to Chemistry: Sources of Antinociceptive Non-Opioid Active Principles for Medicinal Chemistry and Drug Design 120
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 120
Synthesis of (+)-(1'R,2'S) and (1'S,2'R)-6,11 -dimethyl-1,2,3,4,5,6-hexahydro-3-[[2'-(alkoxycarbonyl)-2'- phenylcycloprophy]methyl]-2,6-methano-3-benzazocin-8-ol. Comparison of the affinities for sigma(1) and opioid receptors with in the diastereoisomeric MPCB and CCB 119
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 118
Multitarget opioid ligands in pain relief: New players in an old game 118
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 117
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 116
Analoghi non-peptidici della dinorfina A(1-8): progettazione, sintesi e valutazione farmacologica di agonisti ad elevata selettività Kappa. 116
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partition 115
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 115
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 115
Substituted 1-phenyl-2-cyclopropylmethylamines with high affinity and selectivity for sigma sites 114
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites 114
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 113
Progress in the development of more effective and safer analgesics for pain management 111
Non-peptide ligands for opioid receptors. Design of kappa-specific agonists 109
In-vitro evaluation of a new benzomorphan-based ligand 109
DESIGN, SYNTHESIS, MOLECULAR MODELING AND PHARMACOLOGICAL EVALUATION OF NOVEL DIAZABICYCLO[4.3.0]NONANE AND 2,7-DIAZASPIRO[3.5]NONANE AS SIGMA RECEPTORS LIGANDS 108
Evaluation of N-substitution in 6,7-benzomorphan compounds 107
Idebenone: Novel strategies to improve its systemic and local efficacy 107
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 107
Hybrid MOR agonist/HDACi molecules as potential antinociceptive multi-target drugs: design, synthesis, and biological evaluation 106
Investigation of Tau-Dependent Epigenetic Reprogramming in Alzheimer’s Disease 106
CCB - A novel analog of MPCB with high binding affinity and specific kappa opioid receptor agonist 106
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 104
Nonpeptide Analogues of Dynorphin A(1-8): Design, Synthesis, and Pharmacological Evaluation of k-Selective Agonists 103
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 103
From agonist to antagonist profile in LP1 analogues through the introduction of different N-substituents in benzomorphan-based ligands 102
Differential scanning calorimetry approach to investigate the transfer of the multitarget opioid analgesic LP1 to biomembrane model 102
Synthesis, Computational Insights, and Evaluation of Novel Sigma Receptors Ligands 101
New developments in opioid receptors ligands 99
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 99
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics for Pain Treatment 98
Design, Synthesis, and Evaluation of Novel (−)‐cis‐N‐Normetazocine Derivatives: In Vitro and Molecular Modeling Insights 98
SYNTHESIS, COMPUTATIONAL INSIGHTS, AND EVALUATION OF NOVEL SIGMA RECEPTORS LIGANDS 96
NOVEL N-NORMETAZOCINE DERIVATIVES WITH SIGMA-1 RECEPTOR ANTAGONIST PROFILE AS POTENTIAL ANALGESICS FOR INFLAMMATORY PAIN MANAGEMENT 96
PET imaging of the opioid system using radioligands: Synthetic approaches and translational applications 96
Synthesis and Pharmacological Evaluation of Peptidomimetic of the Kappa-Opioid Receptors 96
Multitarget opioid ligands as suitable candidates for pain management Pharmacolgical fingerprint of the benzomorphan-based opioid compound LP1 96
New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands 96
Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic connexin 43 in an animal model of neuropathic pain 95
Totale 14.232
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022724 0 0 9 24 134 11 119 33 84 26 36 248
2022/20231.755 139 95 29 238 131 263 6 341 359 34 80 40
2023/20241.080 55 136 51 40 56 258 67 108 8 30 185 86
2024/20253.374 83 516 150 226 662 424 229 134 218 260 224 248
2025/20268.285 470 387 2.036 506 1.059 1.411 788 199 418 448 298 265
2026/2027647 331 282 34 0 0 0 0 0 0 0 0 0
Totale 18.126